PTCT — PTC Therapeutics Inc

Ownership history in MPM BioImpact LLC  ·  6 quarters on record

This page tracks every 13F SEC filing in which MPM BioImpact LLC reported a position in PTC Therapeutics Inc (PTCT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
4.41% (2025 Q3)
Avg. % of fund
3.17%
First filed
2024 Q3
Last filed
2025 Q4
Quarters held
6
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 430,013 -8,464 -1.9% 3.74% $32.7M $75.96
2025 Q3 UNCHANGED 438,477 — 0% 4.41% $26.9M $61.37
2025 Q2 REDUCED 438,477 -1,500 -0.3% 3.71% $21.4M $48.84
2025 Q1 ADDED 439,977 +5,210 +1.2% 3.85% $22.4M $50.96
2 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    PTCT price (monthly, adj. close)

Other funds also holding PTCT

As of 2025 Q4 — sorted by position size

Palo Alto Investors LP 3Y 7Y 9.56% RTW INVESTMENTS, LP 3Y 7Y 5.89% TANG CAPITAL MANAGEMENT LLC 3Y 7Y 5.63% ARMISTICE CAPITAL, LLC 3Y 7Y 2.53% Parkman Healthcare Partners LLC 3Y 1.16% SECTOR GAMMA AS 3Y 7Y 1.07% Hood River Capital Management LLC 3Y 7Y 0.84% Abacus FCF Advisors LLC 3Y 7Y 0.75% Ikarian Capital, LLC 3Y 0.7% Jefferies Financial Group Inc. 3Y 7Y 0.64%
← Back to MPM BioImpact LLC Holdings